AVANOS MEDICAL, INC. (AVNS)

Quarterly Report Filed: 2026-05-05

Key Insights

The filing shows Q1 2026 results for Avanos Medical with two operating segments: Specialty Nutrition Systems and Pain Management and Recovery, indicating a focused post-divestiture business model following recent restructuring activities.
The company has undergone multi-year restructuring initiatives with employee severance and benefit expenses, suggesting operational optimization efforts to improve profitability and efficiency post-divestiture.
Avanos completed the acquisition of Nexus Medical Inc. in September 2025, adding customer relationships, patents, and trade names to its asset base, representing a strategic expansion of product capabilities and market reach.
The balance sheet includes both revolving credit facilities and term loan facilities with fair value measurements at Level 2 and Level 3, indicating leveraged capital structure that requires monitoring for debt covenant compliance and refinancing risks.

Current Report Filed: 2026-05-05

Key Insights

Avanos Medical announced Q1 2026 earnings results on May 5, 2026, providing investors with operational performance data for the three months ended March 31, 2026.
The 8-K filing is a standard earnings announcement with no material events, executive changes, or significant corporate actions disclosed beyond the quarterly financial results.
The press release content is furnished but not filed, meaning it is not subject to Section 18 liability under the Exchange Act and will not be incorporated into future regulatory filings unless explicitly stated.

Insider Trading Filed: 2026-04-24

Key Insights

CFO Scott Galovan sold 4,228 shares at $24.64 per share on April 22, 2026, through mandatory tax withholding upon vesting of restricted stock units rather than a discretionary stock sale, indicating no negative sentiment about company prospects.
The transaction resulted from vesting of 12,225 time-based restricted share units (TRSUs) awarded exactly one year prior, with only 34.6% of vested shares retained after tax obligations, showing standard equity compensation mechanics.
Galovan maintains a direct beneficial ownership position of 135,596 shares post-transaction, demonstrating continued material stake in the company aligned with shareholder interests.

Insider Trading Filed: 2026-04-24

Key Insights

SVP of Operations Sigfrido Delgado acquired 4,264 shares at $24.64 through vesting of time-based restricted stock units (TRSUs) on April 22, 2026, with 12,036 shares surrendered for tax withholding obligations, indicating a net acquisition of 4,264 shares.
Following this transaction, Delgado maintains direct beneficial ownership of 55,741 common shares, demonstrating sustained equity stake alignment with company performance as a senior executive.
The TRSU vesting represents standard equity compensation practice for senior management and does not indicate discretionary insider buying or selling activity, limiting conclusions about management's confidence in stock direction.

Insider Trading Filed: 2026-04-16

Key Insights

David Pacitti, the CEO of AVANOS MEDICAL, INC., disposed of 21,194 shares of common stock by surrendering them to the issuer to satisfy tax withholding obligations upon the vesting of time-based restricted share units (TRSUs).
The TRSUs were awarded to Pacitti on April 14, 2025 and vested on April 14, 2026, with each TRSU being the economic equivalent of one share of common stock.
Following the reported transaction, Pacitti continues to beneficially own 322,194 shares of AVANOS MEDICAL, INC. common stock.

Current Report Filed: 2026-04-14

Key Insights

Avanos Medical has agreed to be acquired for $25 per share in cash, representing a premium over the current stock price.
The merger agreement includes provisions for the cancellation and cash-out of outstanding equity awards held by Avanos employees.
The merger is subject to customary closing conditions, including approval by a majority of Avanos shareholders and regulatory clearance.

Insider Trading Filed: 2026-03-17

Key Insights

The SEC Form 4 filing shows that Sigfrido Delgado, the SVP of Operations at AVANOS MEDICAL, INC. (AVNS), acquired 15,886 time-based restricted share units (TRSUs) and 37,520 stock options, vesting over the next 3 years. This indicates the company is incentivizing its senior leadership through equity-based compensation.
Delgado's total beneficial ownership of AVNS stock increased to 60,005 shares, suggesting he has a significant stake in the company and is aligned with shareholders' interests.
The timing of the option grant, with a 10-year expiration period, suggests the company is bullish on its long-term prospects and is seeking to retain and motivate its key executive.

Insider Trading Filed: 2026-03-17

Key Insights

John Joseph Hurley, the Principal Accounting Officer of Avanos Medical, Inc., acquired 2,211 time-based restricted share units (TRSUs) that will vest over the next three years, indicating his commitment to the company's long-term success.
Hurley's direct beneficial ownership of Avanos Medical's common stock increased to 13,592 shares following this transaction, further aligning his interests with those of the company's shareholders.
The TRSU award is part of Avanos Medical's 2021 Long Term Incentive Plan, which suggests the company is focused on incentivizing and retaining key personnel through equity-based compensation.

Insider Trading Filed: 2026-03-17

Key Insights

The reporting person, Scott Michael Galovan, the SVP and Chief Financial Officer of AVANOS MEDICAL, INC., has acquired 29,481 shares of the company's common stock through time-based restricted share units (TRSUs) that will vest over the next 3 years.
Galovan has also been granted 69,630 employee stock options that will vest over the next 3 years, indicating the company's commitment to incentivize and retain its key executive.
The total number of shares beneficially owned by Galovan has increased to 139,824, demonstrating his alignment with the company's long-term success.

Insider Trading Filed: 2026-03-17

Key Insights

David Pacitti, the Chief Executive Officer of AVANOS MEDICAL, INC., has been granted 101,341 time-based restricted share units (TRSUs) that will vest over the next three years.
Pacitti has also been granted 239,354 stock options that will vest over the next three years, providing him with a significant long-term incentive to drive the company's performance.
The insider buying activity indicates Pacitti's confidence in the company's future and alignment with shareholders' interests.

Current Report Filed: 2026-03-12

Key Insights

The company has increased the target value of the annual long-term incentive grant for its CEO, David C. Pacitti, from $5,000,000 to $5,500,000, effective in 2026. This suggests the company is investing more in its leadership and aligning executive compensation with long-term performance.
The filing does not mention any other significant changes or events, indicating the company is operating in a stable manner without any major disruptions or announcements.
Investors should monitor the company's financial performance and any future changes in executive compensation or leadership to assess the overall health and strategic direction of the business.

Insider Trading Filed: 2026-03-11

Key Insights

John Joseph Hurley, the Principal Accounting Officer of AVANOS MEDICAL, INC., surrendered 226 shares of common stock to the company to satisfy tax withholding obligations upon the vesting of 647 time-based restricted share units.
The vesting of these restricted share units suggests continued alignment between Hurley's incentives and the company's long-term performance.
The transaction was a relatively small one, with Hurley still holding 11,381 shares of AVNS stock after the transaction.

Insider Trading Filed: 2026-03-11

Key Insights

The reporting person, Scott Michael Galovan, who is the SVP and Chief Financial Officer of Avanos Medical, Inc. (AVNS), surrendered 1,119 shares of common stock to the issuer to satisfy tax withholding obligations upon the vesting of 3,235 time-based restricted share units (TRSUs).
The transaction occurred on March 9, 2026, and Galovan now beneficially owns 110,343 shares of Avanos Medical's common stock directly.
This routine transaction appears to be related to the vesting of Galovan's equity-based compensation and does not indicate any significant change in his overall ownership position or investment stance.

Insider Trading Filed: 2026-03-10

Key Insights

The reporting person, John Joseph Hurley, is the Principal Accounting Officer of Avanos Medical, Inc. and has filed this Form 4 to report changes in his beneficial ownership of the company's common stock.
Hurley acquired 919 performance-based restricted share units (PRSUs) that vested on March 6, 2026, and he surrendered a total of 676 shares to the issuer to satisfy tax withholding obligations upon the vesting of the PRSUs and time-based restricted share units (TRSUs).
The transaction details suggest insider activity related to equity compensation, which could indicate alignment between management and shareholder interests.

Insider Trading Filed: 2026-03-10

Key Insights

The reporting person, Scott Michael Galovan, is the SVP and Chief Financial Officer of AVANOS MEDICAL, INC. (AVNS), indicating his key role within the company.
Galovan acquired 5,907 performance-based restricted share units (PRSUs) on March 6, 2026, which vested on the same date, suggesting alignment between his compensation and company performance.
Galovan sold 5,454 shares to cover tax withholding obligations related to the vesting of his PRSUs and time-based restricted share units (TRSUs), indicating he is actively managing his equity position.

Current Report Filed: 2026-02-26

Key Insights

Avanos Medical announced that it has entered into a letter agreement with Bradley L. Radoff and The Radoff Family Foundation, which includes the nomination of two new independent directors to the Board.
The agreement includes withdrawal of Radoff's previously announced director nomination, as well as standstill and voting commitments from the Radoff Parties.
The nomination of the two new independent directors could signal a positive development in shareholder engagement and potential board refreshment at Avanos.

Annual Report Filed: 2026-02-24

Key Insights

Avanos Medical's 2025 fiscal year saw revenue growth in its Specialty Nutrition Systems and Pain Management and Recovery segments, indicating potential opportunities for expansion in the medical device market.
The company's recent acquisitions of Nexus Medical Inc. and Diros Technology Inc. suggest a focus on inorganic growth and diversifying its product portfolio, which could enhance its competitive position.
Avanos Medical has implemented a multi-year restructuring plan and transformation process, which may improve operational efficiency and profitability, but could also lead to increased costs in the short term.

Current Report Filed: 2026-02-24

Key Insights

Avanos Medical, Inc. reported its financial results for the three months and year ended December 31, 2025, indicating the company's operational performance during this period.
The press release provides details on the company's revenue, profitability, and other key metrics, which investors can use to assess the company's financial health and future prospects.
Investors should review the full press release and financial statements to understand the company's overall business performance and any significant changes or events that occurred during the reported period.

Current Report Filed: 2026-01-13

Key Insights

Avanos Medical, Inc. is presenting at the JP Morgan Healthcare Conference on January 13, 2026, which could provide investors with insights into the company's strategic direction and growth plans.
The company's financial performance and future outlook will likely be a key focus of the presentation, which could impact investor sentiment.
Investors should watch for any updates or guidance related to Avanos Medical's product pipeline, regulatory approvals, or market expansion initiatives.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information